Cargando…

Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease

The low response to vaccines is a well-known problem in cirrhosis. We evaluated the safety and immunogenicity of booster doses in patients with chronic liver disease (CLD), comparing the humoral response in cirrhotic vs. non-cirrhotic patients, and the impact of different factors on immune response....

Descripción completa

Detalles Bibliográficos
Autores principales:	Cossiga, Valentina, Capasso, Mario, Guarino, Maria, Loperto, Ilaria, Brusa, Stefano, Cutolo, Francesco Maria, Attanasio, Maria Rosaria, Lieto, Raffaele, Portella, Giuseppe, Morisco, Filomena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056762/ https://www.ncbi.nlm.nih.gov/pubmed/36983282 http://dx.doi.org/10.3390/jcm12062281

Ejemplares similares

Safety and immunogenicity of booster dose in patients with chronic liver disease
por: Cossiga, V., et al.
Publicado: (2023)

COVID-19 and Fatty Liver Disorders
por: Guarino, Maria, et al.
Publicado: (2023)

Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions
por: Cossiga, Valentina, et al.
Publicado: (2023)

Humoral response to 2-dose BNT162b2 mRNA vaccine for Covid-19 in liver transplant recipients
por: Guarino, M., et al.
Publicado: (2022)

OC.15.2 HUMORAL RESPONSE TO 2-DOSE BNT162B2 MRNA VACCINE FOR COVID-19 IN LIVER TRANSPLANT RECIPIENTS
por: Guarino, M., et al.
Publicado: (2022)

Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!
por: Guarino, Maria, et al.
Publicado: (2022)

Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents
por: Cossiga, Valentina, et al.
Publicado: (2022)

Use of Telemedicine for Chronic Liver Disease at a Single Care Center During the COVID-19 Pandemic: Prospective Observational Study
por: Guarino, Maria, et al.
Publicado: (2020)

COVID-19 in liver transplant recipients: incidence, hospitalization and outcome in an Italian prospective double-centre study
por: Guarino, Maria, et al.
Publicado: (2022)

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case–control study
por: Morisco, Filomena, et al.
Publicado: (2018)

Berberis aristata, Elaeis guineensis and Coffea canephora Extracts Modulate the Insulin Receptor Expression and Improve Hepatic Steatosis in NAFLD Patients: A Pilot Clinical Trial
por: Cossiga, Valentina, et al.
Publicado: (2019)

Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice
por: Invernizzi, Federica, et al.
Publicado: (2022)

Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study
por: Cossiga, Valentina, et al.
Publicado: (2022)

AF.93 COVID-19 IN LIVER TRANSPLANT RECIPIENTS: AN ITALIAN CASE-CONTROL DOUBLE-CENTER STUDY
por: Guarino, M., et al.
Publicado: (2021)

Effectiveness of Hepatitis B Vaccination Campaign in Italy: Towards the Control of HBV Infection for the First Time in a European Country
por: Stroffolini, Tommaso, et al.
Publicado: (2022)

Liver resection is always a good choice for hepatocellular carcinoma (HCC) patients regardless of Barcelona Clinic Liver Cancer (BCLC) stage: the therapeutic hierarchy
por: Guarino, Maria, et al.
Publicado: (2020)

Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma
por: Guarino, Maria, et al.
Publicado: (2022)

Coffee Restores Expression of lncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD
por: Di Mauro, Stefania, et al.
Publicado: (2021)

Ribociclib in newly diagnosed hepatitis B infection: A case report
por: Di Costanzo, Fabrizio, et al.
Publicado: (2023)

Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients
por: Wroński, Jakub, et al.
Publicado: (2022)

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022)

The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice
por: Cossiga, Valentina, et al.
Publicado: (2021)

Multiple Sclerosis in the Campania Region (South Italy): Algorithm Validation and 2015–2017 Prevalence
por: Moccia, Marcello, et al.
Publicado: (2020)

Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients
por: Federico, Alessandro, et al.
Publicado: (2019)

Long-term immunogenicity of hepatitis B vaccine and impact of a booster dose on health care
por: Bijani, Behzad, et al.
Publicado: (2019)

Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial
por: Omma, Ahmet, et al.
Publicado: (2022)

Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies
por: Vargas, Leonardo, et al.
Publicado: (2022)

Visceral Obesity and Cytokeratin-18 Antigens as Early Biomarkers of Liver Damage
por: de Alteriis, Giulia, et al.
Publicado: (2023)

Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults
por: Zhang, Yuntao, et al.
Publicado: (2022)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
por: Launay, Odile, et al.
Publicado: (2022)

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis
por: Morisco, Filomena, et al.
Publicado: (2014)

Immunogenicity Is Not Improved by Increased Antigen Dose or Booster Dosing of Seasonal Influenza Vaccine in a Randomized Trial of HIV Infected Adults
por: Cooper, Curtis, et al.
Publicado: (2011)

Risk Factors Analysis of Surgical Infection Using Artificial Intelligence: A Single Center Study
por: Scala, Arianna, et al.
Publicado: (2022)

Bodybuilding, dietary supplements and hormones use: behaviour and determinant analysis in young bodybuilders
por: Montuori, Paolo, et al.
Publicado: (2021)

Effectiveness of the Booster Dose in Protecting against COVID-19, Colombia 2022
por: Gálvez, Jubby Marcela, et al.
Publicado: (2023)

636. Immunogenicity, Safety and Tolerability of a Booster Dose of Clostridium difficile Vaccine and 4 Year Antibody Persistence
por: Remich, Shon A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8k893rlr597ason07oblq7aluq